Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average (2016 - 2025)

China Pharma Holdings filings provide 15 years of Equity Average readings, the most recent being $15.5 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 117.52% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 117.52% increase, with the full-year FY2025 number at $15.2 million, up 100.54% from a year prior.
  • Equity Average hit $15.5 million in Q4 2025 for China Pharma Holdings, up from $7.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $15.5 million in Q4 2025 to a low of $3.4 million in Q3 2022.
  • Median Equity Average over the past 5 years was $6.7 million (2023), compared with a mean of $6.6 million.
  • Biggest five-year swings in Equity Average: plummeted 48.73% in 2022 and later soared 117.52% in 2025.
  • China Pharma Holdings' Equity Average stood at $6.4 million in 2021, then plummeted by 44.65% to $3.6 million in 2022, then skyrocketed by 90.39% to $6.8 million in 2023, then rose by 5.24% to $7.1 million in 2024, then surged by 117.52% to $15.5 million in 2025.
  • The last three reported values for Equity Average were $15.5 million (Q4 2025), $7.4 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.